Important Information – Please Read Before Using This Policy

These services may or may not be covered by all Medica plans. Please refer to the member’s plan document for specific coverage information. If there is a difference between this general information and the member’s plan document, the member’s plan document will be used to determine coverage. With respect to Medicare, Medicaid and MinnesotaCare members, this policy will apply unless these programs require different coverage. Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Medica coverage policy may call the Medica Provider Service Center toll-free at 1-800-458-5512.

Medica coverage policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care and treatment.

Coverage Policy
Serum drug levels and antibody levels to monitor TNF inhibitors are investigative, and therefore NOT COVERED.

Note: See also related Medica Coverage Policy, Serological Markers for Diagnosis and Management of Inflammatory Bowel Disease (IBD) or Irritable Bowel Syndrome (IBS).

Description
Tumor necrosis factors (TNF) block the action of a protein, TNF-alpha, which is made by the body’s immune system. Certain immune system diseases, such as rheumatoid arthritis and Crohn’s disease, produce excessive amounts of TNF-alpha that cause the immune system to attack healthy cells, which leads to an inflammatory response. TNF inhibitors can block the action of TNF-alpha thereby reducing the inflammation. TNF inhibitors include, but are not limited to, infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), golimumab (Simponi), and certolizumab pegol (Cimzia).

During use, some patients develop anti-drug antibodies that neutralize the anti-inflammatory action of these drugs. This response may diminish the potential long-term efficacy of these drugs. Blood tests to measure and monitor both the serum drug level and antibody level to these drugs has been proposed as a mechanism to determine a patient’s loss of response to the drug.

FDA Approval
Laboratory tests are regulated under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. Premarket approval from the FDA is not required as long as the assay is performed in a laboratory facility that observes the CLIA regulations and does not market the test for distribution. The Anser IFX (infliximab) and Anser ADA (adalimumab) tests are developed by Prometheus Laboratories Inc. which is an accredited CLIA laboratory.
**Prior Authorization**
Prior authorization is not applicable. Claims for this service are subject to retrospective review and denial of coverage, as investigative services are not eligible for reimbursement.

**Coding Considerations**
Use the current applicable CPT/HCPCS code(s). The following codes are included below for informational purposes only, and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

**CPT Codes:**
- 84999 - Unlisted chemistry procedure

Original Effective Date: 4/1/2011

Re-Review Date(s): 10/22/2013
- 3/18/2015
- 12/21/2016

© 2011- 2017 Medica. Medica® is a registered service mark of Medica Health Plans. "Medica" refers to the family of health plan businesses that includes Medica Health Plans, Medica Health Plans of Wisconsin, Medica Insurance Company, and Medica Self-Insured, and Medica Health Management, LLC.